8-K: Ainos Inc. Expands Product Development Agreement with TCNT, Secures Exclusive Patent Rights for Medical Oxygen Machine

Ainos, Inc. has entered into a third addendum to its product development agreement with Taiwan Carbon Nano Technology Corporation (TCNT), securing exclusive rights to patents for a nitrogen-oxygen separation machine for medical applications.

Summary

• Ainos, Inc. has expanded its existing product development agreement with Taiwan Carbon Nano Technology Corporation (TCNT).
• The third addendum to the agreement includes the co-development, exclusive sales rights, and patent authorization for a nitrogen-oxygen separation machine for medical use.
• TCNT will grant Ainos exclusive use of patents related to the machine, changing from a previous non-exclusive arrangement.
• Ainos will pay TCNT $50,000 per month (plus 5% sales tax) for one year for the exclusive patent use, starting October 16, 2024.
• The parties may negotiate payment terms and subsequent licensing methods after the initial year.

Sentiment

Score: 7

Explanation: The document indicates a positive development for Ainos with the expansion of its product portfolio and securing exclusive patent rights. However, the ongoing costs and future negotiations introduce some uncertainty.

Positives

• Ainos secures exclusive rights to patents for a nitrogen-oxygen separation machine, enhancing its competitive position.
• The agreement expands Ainos' product portfolio into the medical oxygen market.
• The exclusive patent use provides Ainos with a competitive advantage in the market.
• The agreement includes co-development, potentially leading to further innovation and product enhancements.

Negatives

• Ainos will incur a cost of $50,000 per month (plus 5% sales tax) for one year for the exclusive patent use.
• The agreement requires ongoing negotiations for payment terms and subsequent licensing methods after the initial year.

Risks

• The success of the nitrogen-oxygen separation machine is dependent on market demand and regulatory approvals.
• The ongoing negotiations for payment terms and subsequent licensing methods could lead to disagreements or unfavorable terms.
• The company is reliant on TCNT for the technology and manufacturing of the product.

Future Outlook

The parties will negotiate payment terms and subsequent licensing methods after the initial one-year period for the exclusive patent use.

Management Comments

• The company has entered into a third addendum to the Product Development Agreement with TCNT to add co-development, exclusive sales rights and patent authorization of certain nitrogen-oxygen separation machine for certain medical applications.

Industry Context

The agreement positions Ainos to enter the medical oxygen market, which is experiencing growth due to increasing healthcare needs and technological advancements. This move could allow Ainos to diversify its product offerings and potentially capture a significant market share.

Comparison to Industry Standards

• The agreement is similar to other collaborations in the medical device industry where companies partner to develop and commercialize new technologies.
• The exclusive patent rights are a significant advantage, as many companies in the medical device sector rely on licensing agreements to access key technologies.
• The monthly fee of $50,000 plus tax for exclusive patent use is within the range of similar licensing agreements in the industry, but the specific value depends on the technology and market potential.

Related Party Transactions

• TCNT controls the company via its majority interest in Ainos Inc., a Cayman Islands corporation (Ainos KY) and its direct ownership in the Company.
• Ainos KY is a shareholder of the Company and a party to certain previously disclosed Voting Agreements, and controls approximately 62.9% of the voting power of the Company as of October 17, 2024.

Stakeholder Impact

• Shareholders may view this agreement positively due to the potential for new revenue streams and market expansion.
• Employees may see new opportunities for growth and development within the company.
• Customers may benefit from the availability of new medical products.
• Suppliers may see increased demand for raw materials and components.

Next Steps

• Ainos will begin paying the monthly fee for exclusive patent use starting October 16, 2024.
• The parties will negotiate payment terms and subsequent licensing methods after the initial one-year period.
• Ainos will begin co-developing the nitrogen-oxygen separation machine with TCNT.

Key Dates

Keywords

product development, nitrogen-oxygen separation, medical devices, patents, exclusive rights, TCNT, licensing, pharmaceuticals